What is the role of genetic testing in the management of age-related macular degeneration (AMD)?

Updated: Nov 11, 2019
  • Author: Lucia Sobrin, MD, MPH; Chief Editor: Karl S Roth, MD  more...
  • Print


The genetic variants explain about half of the classical sibling risk of AMD, and commercial genetic testing for some AMD risk variants is currently available. Knowledge of genetic variation at risk loci increases the ability to predict AMD progression above and beyond knowledge of demographics, ocular factors, smoking history, and BMI. [2, 4, 32]

Genotyping may become a useful tool for identifying individuals who are at higher risk for disease and thus may benefit from more intense monitoring and/or preventive treatment strategies. Results from several well-powered, ongoing pharmacogenetic studies should clarify whether genetic make-up influences response to treatment in AMD, as suggested by some studies. [33, 32]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!